Roche Holding (RHHBY)
(Delayed Data from OTC)
$41.70 USD
-0.04 (-0.10%)
Updated Aug 28, 2024 04:00 PM ET
2-Buy of 5 2
B Value C Growth B Momentum B VGM
Roche Holding AG (RHHBY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$40.15 | $40.30 | $40.00 | -3.81% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Roche Holding AG comes to $40.15. The forecasts range from a low of $40.00 to a high of $40.30. The average price target represents a decline of 3.81% from the last closing price of $41.74.
Analyst Price Targets (2 )
Broker Rating
Roche Holding AG currently has an average brokerage recommendation (ABR) of 3.18 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 3.18 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, one is Strong Buy, representing 9.09% of all recommendations. A month ago, Strong Buy represented 9.09%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RHHBY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 3.18 | 3.18 | 3.18 | 3.18 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/26/2024 | Not Identified | Not Identified | Hold | Hold |
7/25/2024 | Not Identified | Not Identified | Hold | Hold |
7/2/2024 | Berenberg Bank | Luisa Hector | Hold | Hold |
5/30/2024 | Goldman Sachs | James Quigley | Not Available | Strong Sell |
5/20/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/6/2024 | UBS | Matthew Weston | Hold | Hold |
4/1/2024 | Cowen & Co. | Steve M Scala | Hold | Hold |
3/5/2024 | Argus Research Corp. | Research Department | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.18 |
ABR (Last week) | 3.18 |
# of Recs in ABR | 11 |
Average Target Price | $40.15 |
LT Growth Rate | 3.80% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 103 of 253 |
Current Quarter EPS Est: | 1.46 |